Trump administration considering block grants for Medicaid

The Trump administration is preparing to allow states to remodel their Medicaid programs with block grant proposals, according to a report from The Wall Street Journal, which cited people familiar with ongoing discussions.

The alleged reforms would align with proposals from Republicans to restructure Medicaid with block grants––which allow states to determine how to spend a predetermined set of funds––during their effort to repeal and replace the Affordable Care Act, the WSJ reported. States would still have to follow some requirements but would have more freedom to design their Medicaid programs and apply for waivers to further make changes.

Proponents of block grants argue the reform gives states more flexibility and helps lower costs. Opponents worry block grants could lead to less coverage for beneficiaries and more uninsured people.

CMS has reportedly considered issuing a guidance to allow block grants since the summer, according to the WSJ. The agency has already issued several guidances that allow states to circumvent some Obamacare requirements, including expanding short-term limited-duration health plans. CMS has also allowed a handful of states to implement work requirements for some Medicaid beneficiaries.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.